Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC–MS/MS

Almonertinib was included in the first‐line treatment of non‐small cell lung cancer with EGFR T790M mutations by the Chinese Society of Clinical Oncology in 2021. Considering that immunocompromised lung cancer patients are prone to opportunistic fungal infections, and most triazole antifungal drugs...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedical chromatography 2023-01, Vol.37 (1), p.e5525-n/a
Hauptverfasser:	Fu, Yuhao, Li, Ying, Ma, Yinling, He, Xueru, Xun, Xuejiao, Cui, Yanjun, Fan, Liju, Dong, Zhanjun
Format:	Artikel
Sprache:	eng
Schlagworte:	almonertinib Animals Carcinoma, Non-Small-Cell Lung Chromatography, High Pressure Liquid - methods Chromatography, Liquid - methods drug–drug interaction ErbB Receptors Fluconazole - pharmacology Humans Lung Neoplasms Mutation pharmacokinetics Protein Kinase Inhibitors Rats Reproducibility of Results Tandem Mass Spectrometry - methods triazole antifungal drugs UPLC–MS/MS Voriconazole
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!